Cheng, Nicholas; McLaverty, Alison; Nelson, Barnaby; Markulev, Connie; Schäfer, Miriam R; Berger, Maximus; Mossaheb, Nilufar; Schlögelhofer, Monika; Smesny, Stefan; Hickie, Ian B; Berger, Gregor E; Chen, Eric Y H; de Haan, Lieuwe; Nieman, Dorien H; Nordentoft, Merete; Riecher-Rössler, Anita; Verma, Swapna; Street, Rebekah; Thompson, Andrew; Yuen, Hok Pan; ... (2022). Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial. BJPsych open, 8(5), e165. The Royal College of Psychiatrists 10.1192/bjo.2022.572
|
Text
effects_of_omega3_polyunsaturated_fatty_acid_supplementation_on_cognitive_functioning_in_youth_at_ultrahigh_risk_for_psychosis_secondary_analysis_of_the_neurapro_randomised_controlled_trial.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (361kB) | Preview |
BACKGROUND
Cognitive impairments are well-established features of psychotic disorders and are present when individuals are at ultra-high risk for psychosis. However, few interventions target cognitive functioning in this population.
AIMS
To investigate whether omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation improves cognitive functioning among individuals at ultra-high risk for psychosis.
METHOD
Data (N = 225) from an international, multi-site, randomised controlled trial (NEURAPRO) were analysed. Participants were given omega-3 supplementation (eicosapentaenoic acid and docosahexaenoic acid) or placebo over 6 months. Cognitive functioning was assessed with the Brief Assessment of Cognition in Schizophrenia (BACS). Mixed two-way analyses of variance were computed to compare the change in cognitive performance between omega-3 supplementation and placebo over 6 months. An additional biomarker analysis explored whether change in erythrocyte n-3 PUFA levels predicted change in cognitive performance.
RESULTS
The placebo group showed a modest greater improvement over time than the omega-3 supplementation group for motor speed (ηp2 = 0.09) and BACS composite score (ηp2 = 0.21). After repeating the analyses without individuals who transitioned, motor speed was no longer significant (ηp2 = 0.02), but the composite score remained significant (ηp2 = 0.02). Change in erythrocyte n-3 PUFA levels did not predict change in cognitive performance over 6 months.
CONCLUSIONS
We found no evidence to support the use of omega-3 supplementation to improve cognitive functioning in ultra-high risk individuals. The biomarker analysis suggests that this finding is unlikely to be attributed to poor adherence or consumption of non-trial n-3 PUFAs.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy |
UniBE Contributor: |
Berger, Maximus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2056-4724 |
Publisher: |
The Royal College of Psychiatrists |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
12 Sep 2022 11:39 |
Last Modified: |
05 Dec 2022 16:24 |
Publisher DOI: |
10.1192/bjo.2022.572 |
PubMed ID: |
36073014 |
Uncontrolled Keywords: |
Cognition clinical high risk early intervention psychotic disorders randomised controlled trial |
BORIS DOI: |
10.48350/172778 |
URI: |
https://boris.unibe.ch/id/eprint/172778 |
Actions (login required)
 |
Edit item |